Trial Update October 19, 2026

Phase 3 Trial of CagriSema (Cagrilintide) in Pediatric T2D Now Recruiting

On October 19, 2026, a Phase 3 clinical trial involving cagrilintide, as part of the combination CagriSema, was listed with a status of recruiting. The trial, registered as NCT07282613, is titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes."

The study is designed to compare CagriSema to placebo in a pediatric and adolescent population with type 2 diabetes. It is currently in Phase 3 and is in the recruiting stage, according to the trial record.

Cagrilintide remains classified as unapproved and is under research investigation. No results, efficacy data, or safety outcomes have been reported for this trial at this stage. The trial record indicates recruitment status only, without additional posted findings.

Readers seeking more background on cagrilintide can consult the compound overview for further context.

See the full cagrilintide overview

Source: https://clinicaltrials.gov/study/NCT07282613